CPT® Code 81280

Official Description

Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full sequence analysis

Common Language Description

Molecular genetic testing, specifically CPT® Code 81280, is utilized to identify specific gene mutations that are responsible for long QT syndrome (LQTS). LQTS is a rare, inherited cardiac condition characterized by delayed repolarization of the heart, which can lead to serious complications. This condition is particularly sensitive to adrenergic stimulation, such as during exercise or emotional excitement. The genetic mutations associated with LQTS prolong the duration of the ventricular action potential, resulting in an extended QT interval on an electrocardiogram (ECG). Individuals diagnosed with LQTS face an increased risk of developing irregular heart rhythms, experiencing cardiac palpitations, having syncopal episodes (fainting), and potentially suffering sudden cardiac death due to ventricular fibrillation. The mutations that cause LQTS can be inherited in an autosomal dominant or recessive manner. The more severe recessive phenotypes may also be associated with additional physical anomalies, such as syndactyly (fused fingers or toes) and congenital neural deafness. The full sequence analysis performed under CPT® Code 81280 involves a comprehensive examination of gene segments to identify similarities or differences, thereby elucidating relationships among them. This analysis includes studying intrinsic features to locate active sites for post-translational modifications, as well as understanding the gene structures and the distribution of introns, exons, and regulatory elements. Genetic markers are identified through the detection of point mutations or single nucleotide polymorphisms (SNPs). Notably, the most prevalent mutation associated with LQTS, known as LQT1, is located on the KCNQ1 gene on chromosome 11 and is found in approximately 30-35% of individuals diagnosed with this syndrome.

1. Indications

The molecular genetic testing for long QT syndrome gene analyses (CPT® Code 81280) is indicated for individuals who exhibit symptoms or conditions associated with long QT syndrome. These include:

Irregular Heart Rhythms: Patients may experience arrhythmias that can lead to serious complications.
Cardiac Palpitations: Individuals may report sensations of rapid or irregular heartbeats.
Syncopal Episodes: Patients may experience fainting spells, which can be indicative of underlying cardiac issues.
Family History of LQTS: Individuals with a known familial variant of long QT syndrome may require testing to assess their risk.
Congenital Anomalies: Presence of syndactyly or congenital neural deafness may suggest a genetic predisposition to LQTS.

2. Procedure

The procedure for CPT® Code 81280 involves several critical steps to ensure accurate genetic analysis. These steps include:

Sample Collection: A biological sample, typically blood or saliva, is collected from the patient to obtain DNA for analysis.
DNA Extraction: The DNA is extracted from the collected sample using standardized laboratory techniques to ensure purity and integrity.
Full Sequence Analysis: The extracted DNA undergoes full sequence analysis, which involves comparing gene segments to identify mutations. This analysis focuses on specific genes associated with long QT syndrome, including KCNQ1, KCNH2, SCN5A, and others.
Identification of Mutations: The analysis aims to identify point mutations or single nucleotide polymorphisms (SNPs) that may contribute to the development of LQTS. This step is crucial for determining the genetic basis of the condition.
Data Interpretation: The results of the genetic analysis are interpreted by qualified geneticists or molecular biologists, who assess the significance of identified mutations in relation to long QT syndrome.

3. Post-Procedure

After the completion of the genetic testing for long QT syndrome, patients may receive counseling regarding the results. If a mutation is identified, it is recommended that first-degree relatives undergo molecular genetic testing to determine their risk of carrying the same mutation. This genetic mapping can help in understanding familial variants and assessing the risk factors for relatives. Additionally, patients may be advised on monitoring and management strategies to mitigate the risks associated with long QT syndrome, including lifestyle modifications and potential medical interventions.

Short Descr	LONG QT SYND GENE FULL SEQ
Medium Descr	LONG QT SYNDROME FULL SEQUENCE ANALYSIS
Long Descr	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full sequence analysis
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	9 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	Not applicable/unspecified.
CCS Clinical Classification	234 - Pathology